Publication:
Centrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation

dc.contributor.buuauthorÇavun, Sinan
dc.contributor.buuauthorSavcı, Vahide
dc.contributor.buuauthorUlus, İsmail Hakkı
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Farmakoloji Ana Bilim Dalı
dc.contributor.researcheridAAC-9702-2019
dc.contributor.researcheridD-5340-2015
dc.contributor.scopusid6507468595
dc.contributor.scopusid6603687024
dc.contributor.scopusid7004271086
dc.date.accessioned2022-03-14T11:51:24Z
dc.date.available2022-03-14T11:51:24Z
dc.date.issued2004-02
dc.description.abstractIn the present study, both the effects of intracerebroventricular (i.c.v.) injection of cytidine-5′-diphosphate choline (CDP-choline) on plasma vasopressin levels and the choline involvement of these effects were investigated. I.c.v. administration of CDP-choline (0.5, 1.0 and 2.0 μmol) increased plasma vasopressin levels dose- and time-dependently. I.c.v. injection of equimolar dose of choline (1 μmol) produced similar vasopressin response. However equimolar dose of cytidine (1 μmol; i.c.v.), the other hydrolysis product of CDP-choline, did not affect plasma vasopressin levels. Pretreatment of rats with hemicholinium-3, neuronal high affinity choline uptake inhibitor (20 μg; i.c.v.) blocked the vasopressin response to i.c.v. CDP-choline (1 μmol). Pretreatment of rats with mecamylamine (50 μg; i.c.v.), a nonselective nicotinic receptor antagonist, abolished the increase in plasma vasopressin induced by CDP-choline while atropine (10 μg; i.c.v.), nonselective muscarinic receptor antagonist, failed to change the response. In conclusion, intracerebroventricularly injected CDP-choline can increase plasma vasopressin levels by activating central nicotinic cholinergic receptors through the activation of presynaptic cholinergic mechanisms.
dc.identifier.citationÇavun, S. vd. (2004). “Centrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation”. Fundamental and Clinical Pharmacology, 18(1), 71-77.
dc.identifier.endpage77
dc.identifier.issn0767-3981
dc.identifier.issue1
dc.identifier.pubmed14748757
dc.identifier.scopus2-s2.0-1042288132
dc.identifier.startpage71
dc.identifier.urihttps://doi.org/10.1046/j.0767-3981.2003.00213.x
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1046/j.0767-3981.2003.00213.x
dc.identifier.urihttp://hdl.handle.net/11452/24992
dc.identifier.volume18
dc.identifier.wos000188963800009
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherWiley
dc.relation.journalFundamental and Clinical Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPharmacology and pharmacy
dc.subjectCDP-choline
dc.subjectCholine
dc.subjectCytidine
dc.subjectNicotinic receptor
dc.subjectPrecursor
dc.subjectVasopressin
dc.subjectRat supraoptic nucleus
dc.subjectConscious rats
dc.subjectAcetylcholine-receptors
dc.subjectRelease
dc.subjectNeurons
dc.subjectHypothalamus
dc.subjectInvolvement
dc.subjectHippocampal
dc.subjectHemorrhage
dc.subjectCiticoline
dc.subject.emtreeAtropine
dc.subject.emtreeCholine
dc.subject.emtreeCiticoline
dc.subject.emtreeCytidine
dc.subject.emtreeHemicholinium 3
dc.subject.emtreeMecamylamine
dc.subject.emtreeMuscarinic receptor blocking agent
dc.subject.emtreeNicotinic receptor
dc.subject.emtreeNicotinic receptor blocking agent
dc.subject.emtreeVasopressin
dc.subject.emtreeAnimal experiment
dc.subject.emtreeArticle
dc.subject.emtreeCholine uptake
dc.subject.emtreeCholinergic activity
dc.subject.emtreeCholinergic system
dc.subject.emtreeControlled study
dc.subject.emtreeDose time effect relation
dc.subject.emtreeDrug effect
dc.subject.emtreeDrug hydrolysis
dc.subject.emtreeDrug mechanism
dc.subject.emtreeDrug response
dc.subject.emtreeInhibition kinetics
dc.subject.emtreeInjection
dc.subject.emtreeMale
dc.subject.emtreeNonhuman
dc.subject.emtreePresynaptic nerve
dc.subject.emtreePriority journal
dc.subject.emtreeProtein blood level
dc.subject.emtreeRat
dc.subject.meshAnimals
dc.subject.meshAtropine
dc.subject.meshCholinergic agents
dc.subject.meshCytidine
dc.subject.meshCytidine diphosphate choline
dc.subject.meshDizocilpine maleate
dc.subject.meshDose-response relationship, drug
dc.subject.meshExcitatory amino acid antagonists
dc.subject.meshHemicholinium 3
dc.subject.meshInjections, intraventricular
dc.subject.meshMale
dc.subject.meshMecamylamine
dc.subject.meshMuscarinic antagonists
dc.subject.meshNicotinic antagonists
dc.subject.meshNootropic agents
dc.subject.meshParasympathetic nervous system
dc.subject.meshRats
dc.subject.meshRats, wistar
dc.subject.meshReceptors, presynaptic
dc.subject.meshStimulation, chemical
dc.subject.meshSynapses
dc.subject.meshVasopressins
dc.subject.scopusCiticoline; Brain Ischemia; Glycerylphosphorylcholine
dc.subject.wosPharmacology and pharmacy
dc.titleCentrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation
dc.typeArticle
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbi Farmakoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: